Targeting novel signaling pathways for resistant acute myeloid leukemia

Molecular Genetics and Metabolism

Volumn 114, Issue 3, 2015, Pages 397-402

  Sakamoto, Kathleen M ^a   Grant, Steven ^b   Saleiro, Diana ^c   Crispino, John D ^c   Hijiya, Nobuko ^c   Giles, Francis ^c   Platanias, Leonidas ^c,d   Eklund, Elizabeth A ^c,d  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

Acute myeloid leukemia; Novel therapies; Resistance; Signaling pathways

Indexed keywords

ANTILEUKEMIC AGENT; BH3 PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN BCL 2; STAT3 PROTEIN; TRIAD1 PROTEIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; ARIH2 PROTEIN, HUMAN; BCL2 PROTEIN, HUMAN; CREB1 PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; UBIQUITIN PROTEIN LIGASE;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER CHEMOTHERAPY; CANCER RESISTANCE; DRUG EFFICACY; DRUG TARGETING; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; ADULT; CHILD; DRUG RESISTANCE; LEUKEMIA, MYELOID, ACUTE; METABOLISM;

ADULT; CHILD; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOID, ACUTE; MOLECULAR TARGETED THERAPY; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TOR SERINE-THREONINE KINASES; UBIQUITIN-PROTEIN LIGASES;

EID: 84924122265     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2014.11.017     Document Type: Review

References (93)

1. Gojo I., Karp J.E. New strategies in acute myelogenous leukemia: leukemogenesis and personalized medicine. Clin. Cancer Res. 2014.
2. Estey E.H. Acute myeloid leukemia: 2014 update on risk-stratification and management. Am. J. Hematol. 2014, 89(11):1063-1081.
3. Perry A.M., Attar E.C. New insights in AML biology from genomic analysis. Semin. Hematol. 2014, 51(4):282-297.
4. Shaywitz A.J., Greenberg M.E. CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu. Rev. Biochem. 1999, 68:821-861.
5. Shankar D.B., Cheng J.C., Kinjo K., Federman N., Moore T.B., Gill A., Rao N.P., Landaw E.M., Sakamoto K.M. The role of CREB as a proto-oncogene in hematopoiesis and in acute myeloid leukemia. Cancer Cell 2005, 7(4):351-362.
6. Shankar D.B., Cheng J.C., Sakamoto K.M. Role of cyclic AMP response element binding protein in human leukemias. Cancer 2005, 104(9):1819-1824.
7. Ma H., Groth R.D., Cohen S.M., Emery J.F., Li B., Hoedt E., Zhang G., Neubert T.A., Tsien R.W. gammaCaMKII shuttles Ca(2+)/CaM to the nucleus to trigger CREB phosphorylation and gene expression. Cell 2014, 159(2):281-294.
8. Cho E.C., Mitton B., Sakamoto K.M. CREB and leukemogenesis. Crit. Rev. Oncog. 2011, 16(1-2):37-46.
9. Esparza S.D., Chang J., Shankar D.B., Zhang B., Nelson S.F., Sakamoto K.M. CREB regulates Meis1 expression in normal and malignant hematopoietic cells. Leukemia 2008, 22(3):665-667.
10. Mora-Garcia P., Cheng J., Crans-Vargas H.N., Countouriotis A., Shankar D., Sakamoto K.M. Transcriptional regulators and myelopoiesis: the role of serum response factor and CREB as targets of cytokine signaling. Stem Cells 2003, 21(2):123-130.
11. Crans-Vargas H.N., Landaw E.M., Bhatia S., Sandusky G., Moore T.B., Sakamoto K.M. Expression of cyclic adenosine monophosphate response-element binding protein in acute leukemia. Blood 2002, 99(7):2617-2619.
12. Sandoval S., Kraus C., Cho E.C., Cho M., Bies J., Manara E., Accordi B., Landaw E.M., Wolff L., Pigazzi M., et al. Sox4 cooperates with CREB in myeloid transformation. Blood 2012, 120(1):155-165.
13. Pigazzi M., Manara E., Bresolin S., Tregnago C., Beghin A., Baron E., Giarin E., Cho E.C., Masetti R., Rao D.S., et al. MicroRNA-34b promoter hypermethylation induces CREB overexpression and contributes to myeloid transformation. Haematologica 2013, 98(4):602-610.
14. Pigazzi M., Manara E., Baron E., Basso G. miR-34b targets cyclic AMP-responsive element binding protein in acute myeloid leukemia. Cancer Res. 2009, 69(6):2471-2478.
15. Cheng J.C., Esparza S., Sandoval S., Shankar D., Fu C., Sakamoto K.M. Potential role of CREB as a prognostic marker in acute myeloid leukemia. Future Oncol. 2007, 3(4):475-480.
16. Cheng J.C., Kinjo K., Judelson D.R., Chang J., Wu W.S., Schmid I., Shankar D.B., Kasahara N., Stripecke R., Bhatia R., et al. CREB is a critical regulator of normal hematopoiesis and leukemogenesis. Blood 2008, 111(3):1182-1192.
17. Xiao X., Li B.X., Mitton B., Ikeda A., Sakamoto K.M. Targeting CREB for cancer therapy: friend or foe. Curr. Cancer Drug Targets 2010, 10(4):384-391.
18. Marteijn J.A., van Emst L., Erpelinck-Verschueren C.A., Nikoloski G., Menke A., de Witte T., Löwenberg B., Jansen J.H., van der Reijden B.A. The E3 ubiquitin-protein ligase Triad1 inhibits clonogenic growth of primary myeloid progenitor cells. Blood 2005, 106(13):4114-4123.
19. Marteijn J.A., van der Meer L.T., Smit J.J., Noordermeer S.M., Wissink W., Jansen P., Swarts H.G., Hibbert R.G., de Witte T., Sixma T.K., Jansen J.H., van der Reijden B.A. The ubiquitin ligase Triad1 inhibits myelopoiesis through UbcH7 and Ubc13 interacting domains. Leukemia 2009, 23(8):1480-1489.
20. Pietschmann K., Buchwald M., Müller S., Knauer S.K., Kögl M., Heinzel T., Krämer O.H. Differential regulation of PML-RARα stability by the ubiquitin ligases SIAH1/SIAH2 and TRIAD1. Int. J. Biochem. Cell Biol. 2012, 44(1):132-138.
21. Hassink G., Slotman J., Oorschot V., Van Der Reijden B.A., Monteferrario D., Noordermeer S.M., Van Kerkhof P., Klumperman J., Strous G.J. Identification of the ubiquitin ligase Triad1 as a regulator of endosomal transport. Biol. Open 2012, 1(6):607-614.
22. Jung J.H., Lee S.M., Bae S., Lee S.J., Park I.C., Jin Y.W., Lee J.H., An S. Triad 1 induces apoptosis by p53 activation. FEBS Lett. 2010, 584:1565-1570.
23. Kelsall I.R., Duda D.M., Olszewski J.L., Hofmann K., Knebel A., Langevin F., Wood N., Wightman M., Schulman B.A., Alpi A.F. TRIAD1 and HHARI bind to and are activated by distinct neddylated Cullin-RING ligase complexes. EMBO J. 2013, 32(21):2848-2860.
24. Ding V.M., Ling L., Natarajan S., Yap M.G., Cool S.M., Choo A.B. FGF-2 modulates Wnt signaling in undifferentiated hESC and iPS cells through activated PI3-K/GSK3B signaling. J. Cell. Physiol. 2010, 225(2):417-428.
25. Lin A.E., Ebert G., Ow Y., Preston S.P., Toe J.G., Cooney J.P., Scott H.W., Sasaki M., Saibil S.D., Dissanayake D., Kim R.H., Wakeham A., You-Ten A., Shahinian A., Duncan G., Silvester J., Ohashi P.S., Mak T.W., Pellegrini M. ARIH2 is essential for embryogenesis, and its hematopoietic deficiency causes lethal activation of the immune system. Nat. Immunol. 2013, 14(1):27-33.
26. Johansson B., Billström R., Kristoffersson U., Akerman M., Garwicz S., Ahlgren T., Malm C., Mitelman F. Deletion of chromosome arm 3p in hematologic malignancies. Leukemia 1997, 11(8):1207-1213.
27. Shi G., Weh H.J., Martensen S., Seeger D., Hossfeld D.K. 3p21 is a recurrent treatment-related breakpoint in myelodysplastic syndrome and acute myeloid leukemia. Cytogenet. Cell Genet. 1996, 74(94):295-299.
28. Zhu X., He F., Zeng H., Ling S., Chen A., Wang Y., Yan X., Wei W., Pang Y., Cheng H., Hua C., Zhang Y., Yang X., Lu X., Cao L., Hao L., Dong L., Zou W., Wu J., Li X., Zheng S., Yan J., Zhou J., Zhang L., Mi S., Wang X., Zhang L., Zou Y., Chen Y., Geng Z., Wang J., Zhou J., Liu X., Wang J., Yuan W., Huang G., Cheng T., Wang Q.F. Identification of functional cooperative mutations of SETD2 in human acute leukemia. Nat. Genet. 2014, 46(3):287-293.
29. Oncomine 4.4 Research Edition, Compendia Biosciences, . http://www.oncomine.org/resource/.
30. Drabkin H.A., Parsy C., Ferguson K., Guilhot F., Lacotte L., Roy L., Zeng C., Baron A., Hunger S.P., Varella-Garcia M., Gemmill R., Brizard F., Brizard A., Roche J. Quantitative HOX expression in chromosomally defined subsets of acute myelogenous leukemia. Leukemia 2002, 16(2):186-195.
31. Armstrong S.A., Staunton J.E., Silverman L.B., Pieters R., den Boer M.L., Minden M.D., Sallan S.E., Lander E.S., Golub T.R., Korsmeyer S.J. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat. Genet. 2002, 30(1):41-47.
32. Eklund E.A., Jalava A., Kakar R. Tyrosine phosphorylation decreases HoxA10 DNA-binding and transcriptional repression during IFNγ differentiation in myeloid cell lines. J. Biol. Chem. 2000, 275(26):20117-20126.
33. Lindsay S., Huang W., Wang H., Horvath E., Zhu C., Eklund E.A. Activation of SHP2 protein tyrosine phosphatase increases HoxA10-induced repression of the genes encoding gp91PHOX and p67PHOX. J. Biol. Chem. 2007, 282(4):2237-2249.
34. Bei L., Lu Y.F., Eklund E.A. HoxA9 activates transcription of the gene encoding gp91PHOX during myeloid differentiation. J. Biol. Chem. 2005, 280(13):12359-12370.
35. Camos M., Esteve J., Jares P., Colomer D., Rozman M., Villamor N., Costa D., Carrio A., Nomdedue J., Montserrat E., Campo E. Gene expression profiling of acute myeloid leukemia with translocation t(8;16) (p11;q13) and MYST3-CREBBP rearrangement reveals a distinctive signature with a specific pattern of HOX gene expression. Cancer Res. 2006, 66(14):6947-6954.
36. Li Z., Luo R.T., Mi S., Sun M., Chen P., Bao J., Neilly M.B., Jayathilaka N., Johnson D.S., Wang L., Lavau C., Zhang Y., Tseng C., Zhang X., Wang J., Yu J., Yang H., Wang S.M., Rowley J.D., Chen J., Thirman M.J. Consistent deregulation of gene expression between human and murine MLL rearrangement leukemias. Cancer Res. 2009, 69(3):1109-1116.
37. Thorsteinsdottir U., Sauvageau G., Hough M.R., Dragowska W., Lansdorp P.M., Lawrence H.J., Largman C., Humphries R.K. Overexpression of HoxA10 in murine hematopoietic cells perturbs both myeloid and lymphoid differentiation and leads to acute myeloid leukemia. Mol. Cell. Biol. 1997, 17(1):495-505.
38. Bjornsson J.M., Andersson E., Lundstrom P., Larsson N., Xu X., Repetowska E., Humphries K.R., Karlsson S. Proliferation of primitive myeloid progenitors can be reversibly induced by HOXA10. Blood 2001, 98(12):3301-3308.
39. Balgobind B.V., Hollink I.H., Arentsen-Peters S.T., Zimmermann M., Harbott J., Beverloo H.B., von Bergh A.R., Cloos J., Kaspers G.J., de Haas V., Zemanova Z., Stary J., Cayuela J.M., Baruchel A., Creutzig U., Reinhardt D., Pieters R., Zwaan C.M., van den Heuvel-Eibrink M.M. Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia. Haematologica 2011, 96(10):1478-1487.
40. Nabinger S.C., Li X.J., Ramdas B., He Y., Zhang X., Zeng L., Richine B., Bowling J.D., Fukuda S., Goenka S., Liu Z., Feng G.S., Yu M., Sandusky G.E., Boswell H.S., Zhang Z.Y., Kapur R., Chan R.J. The protein tyrosine phosphatase, Shp2, positively contributes to FLT3-ITD-induced hematopoietic progenitor hyperproliferation and malignant disease in vivo. Leukemia 2013, 27(2):398-408.
41. Krivtsov A.V., Figueroa M.E., Sinha A.U., Stubbs M.C., Feng Z., Valk P.J., Delwel R., Dohner K., Bullinger L., Kung A.L., et al. Cell of origin determines clinically relevant subtypes of MLL-rearranged AML. Leukemia Apr 2013, 27(4):852-860.
42. Neff T., Armstrong S.A. Recent progress toward epigenetic therapies: the example of mixed lineage leukemia. Blood Jun 13 2013, 121(24):4847-4853. (PMCID:PMC3682337).
43. de B.J., Walf-Vorderwulbecke V., Williams O. In focus: MLL-rearranged leukemia. Leukemia Jun 2013, 27(6):1224-1228.
44. Del P.G., Bruno A., Del Principe M.I., Venditti A., Maurillo L., Buccisano F., Stasi R., Neri B., Luciano F., Siniscalchi A., et al. Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia. Curr. Cancer Drug Targets May 2008, 8(3):207-222.
45. Beurlet S., Omidvar N., Gorombei P., Krief P., Le P.C., Setterblad N., de la Grange P., Leboeuf C., Janin A., Noguera M.E., et al. BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells. Blood Oct 17 2013, 122(16):2864-2876.
46. Pan R., Hogdal L.J., Benito J.M., Bucci D., Han L., Borthakur G., Cortes J., DeAngelo D.J., Debose L., Mu H., et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. Mar 2014, 4(3):362-375.
47. Vo T.T., Ryan J., Carrasco R., Neuberg D., Rossi D.J., Stone R.M., DeAngelo D.J., Frattini M.G., Letai A. Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell Oct 12 2012, 151(2):344-355.
48. Niu X., Wang G., Wang Y., Caldwell J.T., Edwards H., Xie C., Taub J.W., Li C., Lin H., Ge Y. Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199. Leukemia Jul 2014, 28(7):1557-1560.
49. Ewings K.E., Hadfield-Moorhouse K., Wiggins C.M., Wickenden J.A., Balmanno K., Gilley R., Degenhardt K., White E., Cook S.J. ERK1/2-dependent phosphorylation of Bim(EL) promotes its rapid dissociation from Mcl-1 and Bcl-x(L). EMBO J. May 24 2007, 26:2856-2867.
50. Konopleva M., Milella M., Ruvolo P., Watts J.C., Ricciardi M.R., Korchin B., McQueen T., Bornmann W., Tsao T., Bergamo P., et al. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex. Leukemia 2012, 26(4):778-787.
51. Martelli A.M., Evangelisti C., Chiarini F., McCubrey J.A. The phosphatidylinositol 3- kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget Jun 2010, 1(2):89-103.
52. Maurer U., Charvet C., Wagman A.S., Dejardin E., Green D.R. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol. Cell Mar 17 2006, 21(6):749-760.
53. Rahmani M., Aust M.M., Attkisson E., Williams D.C., Ferreira-Gonzalez A., Grant S. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism. Cancer Res. Feb 15 2013, 73(4):1340-1351. (41).
54. Forman S.J., Rowe J.M. The myth of the second remission of acute leukemia in the adult. Blood 2013, 121(7):1077-1082.
55. Ding L., Ley T.J., Larson D.E., Miller C.A., Koboldt D.C., Welch J.S., Ritchey J.K., Young M.A., Lamprecht T., McLellan M.D., McMichael J.F., Wallis J.W., Lu C., Shen D., Harris C.C., Dooling D.J., Fulton R.S., Fulton L.L., Chen K., Schmidt H., Kalicki-Veizer J., Magrini V.J., Cook L., McGrath S.D., Vickery T.L., Wendl M.C., Heath S., Watson M.A., Link D.C., Tomasson M.H., Shannon W.D., Payton J.E., Kulkarni S., Westervelt P., Walter M.J., Graubert T.A., Mardis E.R., Wilson R.K., DiPersio J.F. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012, 481(7382):506-510.
56. Parkin B., Ouillette P., Li Y., Keller J., Lam C., Roulston D., Li C., Shedden K., Malek S.N. Clonal evolution and devolution after chemotherapy in adult acute myelogenous leukemia. Blood 2013, 121(2):369-377.
57. Corces-Zimmerman M.R., Hong W.J., Weissman I.L., Medeiros B.C., Majeti R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc. Natl. Acad. Sci. U. S. A. 2014, 111(7):2548-2553.
58. Shlush L.I., Zandi S., Mitchell A., Chen W.C., Brandwein J.M., Gupta V., Kennedy J.A., Schimmer A.D., Schuh A.C., Yee K.W., McLeod J.L., Doedens M., Medeiros J.J., Marke R., Kim H.J., Lee K., McPherson J.D., Hudson T.J., HALT Pan-Leukemia Gene Panel Consortium, Brown A.M., Yousif F., Trinh Q.M., Stein L.D., Minden M.D., Wang J.C., Dick J.E. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 2014, 506(7488):328-333.
59. Welch J.S., Ley T.J., Link D.C., Miller C.A., Larson D.E., Koboldt D.C., Wartman L.D., Lamprecht T.L., Liu F., Xia J., Kandoth C., Fulton R.S., McLellan M.D., Dooling D.J., Wallis J.W., Chen K., Harris C.C., Schmidt H.K., Kalicki-Veizer J.M., Lu C., Zhang Q., Lin L., O'Laughlin M.D., McMichael J.F., Delehaunty K.D., Fulton L.A., Magrini V.J., McGrath S.D., Demeter R.T., Vickery T.L., Hundal J., Cook L.L., Swift G.W., Reed J.P., Alldredge P.A., Wylie T.N., Walker J.R., Watson M.A., Heath S.E., Shannon W.D., Varghese N., Nagarajan R., Payton J.E., Baty J.D., Kulkarni S., Klco J.M., Tomasson M.H., Westervelt P., Walter M.J., Graubert T.A., DiPersio J.F., Ding L., Mardis E.R., Wilson R.K. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012, 150(2):264-278.
60. Laplante M., Sabatini D.M. mTOR signaling in growth control and disease. Cell 2012, 149(2):274-293.
61. Beauchamp E.M., Platanias L.C. The evolution of the TOR pathway and its role in cancer. Oncogene 2013, 32(34):3923-3932. 10.1038/onc.2012.567.
62. Aoki Y., Matsubara Y. Ras/MAPK syndromes and childhood hemato-oncological diseases. Int. J. Hematol. 2013, 97(1):30-36.
63. Pritchard A.L., Hayward N.K. Molecular pathways: mitogen-activated protein kinase pathway mutations and drug resistance. Clin. Cancer Res. 2013, 19(9):2301-2309.
64. Geest C.R., Coffer P.J. MAPK signaling pathways in the regulation of hematopoiesis. J. Leukoc. Biol. 2009, 86(2):237-250.
65. Volk A., Li J., Xin J., You D., Zhang J., Liu X., Xiao Y., Breslin P., Li Z., Wei W., Schmidt R., Li X., Zhang Z., Kuo P.C., Nand S., Zhang J., Chen J., Zhang J. Co-inhibition of NF-κB and JNK is synergistic in TNF-expressing human AML. J. Exp. Med. 2014, 211(6):1093-1108.
66. Altman J.K., Glaser H., Sassano A., Joshi S., Ueda T., Watanabe-Fukunaga R., Fukunaga R., Tallman M.S., Platanias L.C. Negative regulatory effects of Mnk kinases in the generation of chemotherapy-induced antileukemic responses. Mol. Pharmacol. 2010, 78(4):778-784.
67. Altman J.K., Szilard A., Konicek B.W., Iversen P.W., Kroczynska B., Glaser H., Sassano A., Vakana E., Graff J.R., Platanias L.C. Inhibition of Mnk kinase activity by cercosporamide and suppressive effects on acute myeloid leukemia precursors. Blood 2013, 121(18):3675-3681.
68. Altman J.K., Platanias L.C. Acute myeloid leukemia: potential for new therapeutic approaches targeting mRNA translation pathways. Int. J. Hematol. Oncol. 2013, 2(3). 10.2217/ijh.13.23.
69. Altman J.K., Sassano A., Kaur S., Glaser H., Kroczynska B., Redig A.J., Russo S., Barr S., Platanias L.C. Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors. Clin. Cancer Res. 2011, 17(13):4378-4388.
70. Zeng Z., Shi Y.X., Tsao T., Qiu Y., Kornblau S.M., Baggerly K.A., Liu W., Jessen K., Liu Y., Kantarjian H., Rommel C., Fruman D.A., Andreeff M., Konopleva M. Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment. Blood 2012, 120(13):2679-2689.
71. Willems L., Chapuis N., Puissant A., Maciel T.T., Green A.S., Jacque N., Vignon C., Park S., Guichard S., Herault O., Fricot A., Hermine O., Moura I.C., Auberger P., Ifrah N., Dreyfus F., Bonnet D., Lacombe C., Mayeux P., Bouscary D., Tamburini J. The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. Leukemia 2012, 26(6):1195-1202.
72. Kampa-Schittenhelm K.M., Heinrich M.C., Akmut F., Rasp K.H., Illing B., Döhner H., Döhner K., Schittenhelm M.M. Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia. Mol. Cancer 2013, 12:46. 10.1186/1476-4598-12-46.
73. Chapuis N., Tamburini J., Green A.S., Vignon C., Bardet V., Neyret A., Pannetier M., Willems L., Park S., Macone A., Maira S.M., Ifrah N., Dreyfus F., Herault O., Lacombe C., Mayeux P., Bouscary D. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin. Cancer Res. 2010, 16(22):5424-5435. 10.1158/1078-0432.CCR-10-1102.
74. Stead R.L., Proud C.G. Rapamycin enhances eIF4E phosphorylation by activating MAP kinase-interacting kinase 2a (Mnk2a). FEBS Lett. 2013, 587(16):2623-2628.
75. Greger J.G., Eastman S.D., Zhang V., Bleam M.R., Hughes A.M., Smitheman K.N., Dickerson S.H., Laquerre S.G., Liu L., Gilmer T.M. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol. Cancer Ther. 2012, 11(4):909-920.
76. Brundage M.E., Tandon P., Eaves D.W., Williams J.P., Miller S.J., Hennigan R.H., Jegga A., Cripe T.P., Ratner N. MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. Oncogene 2014, (Epub ahead of print). 10.1038/onc.2013.506.
77. Zhang W., Ruvolo V.R., Gao C., Zhou L., Bornmann W., Tsao T., Schober W.D., Smith P., Guichard S., Konopleva M., Andreeff M. Evaluation of apoptosis induction by concomitant inhibition of MEK, mTOR, and Bcl-2 in human acute myelogenous leukemia cells. Mol. Cancer Ther. 2014, 13(7):1848-1859.
78. Levine R.L., Pardanani A., Tefferi A., Gilliland D.G. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat. Rev. Cancer 2007, 7(9):673-683.
79. Klampfl T., Gisslinger H., Harutyunyan A.S., Nivarthi H., Rumi E., Milosevic J.D., Them N.C., Berg T., Gisslinger B., Pietra D., Chen D., Vladimer G.I., Bagienski K., Milanesi C., Casetti I.C., Sant'Antonio E., Ferretti V., Elena C., Schischlik F., Cleary C., Six M., Schalling M., Schönegger A., Bock C., Malcovati L., Pascutto C., Superti-Furga G., Cazzola M., Kralovics R. Somatic mutations of calreticulin in myeloproliferative neoplasms. N. Engl. J. Med. 2013, 369(25):2379-2390.
80. Verstovsek S., Kantarjian H., Mesa R.A., Pardanani A.D., Cortes-Franco J., Thomas D.A., Estrov Z., Fridman J.S., Bradley E.C., Erickson-Viitanen S., Vaddi K., Levy R., Tefferi A. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N. Engl. J. Med. 2010, 363(12):1117-1127.
81. Verstovsek S., Mesa R.A., Gotlib J., Levy R.S., Gupta V., DiPersio J.F., Catalano J.V., Deininger M.W., Miller C.B., Silver R.T., Talpaz M., Winton E.F., Harvey J.H., Arcasoy M.O., Hexner E.O., Lyons R.M., Paquette R., Raza A., Vaddi K., Erickson-Viitanen S., Sun W., Sandor V., Kantarjian H.M. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica 2013, 98(12):1865-1871.
82. Tefferi A. JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood 2012, 119(12):2721-2730.
83. Koppikar P., Bhagwat N., Kilpivaara O., Manshouri T., Adli M., Hricik T., Liu F., Saunders L.M., Mullally A., Abdel-Wahab O., Leung L., Weinstein A., Marubayashi S., Goel A., Gönen M., Estrov Z., Ebert B.L., Chiosis G., Nimer S.D., Bernstein B.E., Verstovsek S., Levine R.L. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 2012, 489(7414):155-159.
84. Kalota A., Jeschke G.R., Carroll M., Hexner E.O. Intrinsic resistance to JAK2 inhibition in myelofibrosis. Clin. Cancer Res. 2013, 19(7):1729-1739.
85. Vicente C., Vázquez I., Marcotegui N., Conchillo A., Carranza C., Rivell G., Bandrés E., Cristobal I., Lahortiga I., Calasanz M.J., Odero M.D. JAK2-V617F activating mutation in acute myeloid leukemia: prognostic impact and association with other molecular markers. Leukemia 2007, 21(11):2386-2390.
86. Steensma D.P., McClure R.F., Karp J.E., Tefferi A., Lasho T.L., Powell H.L., DeWald G.W., Kaufmann S.H. JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained. Leukemia 2006, 20(6):971-978.
87. Lo M.C., Peterson L.F., Yan M., Cong X., Hickman J.H., Dekelver R.C., Niewerth D., Zhang D.E. JAK inhibitors suppress t(8;21) fusion protein-induced leukemia. Leukemia 2013, 27(12):2272-2279.
88. Mizuki M., Fenski R., Halfter H., Matsumura I., Schmidt R., Müller C., Grüning W., Kratz-Albers K., Serve S., Steur C., Büchner T., Kienast J., Kanakura Y., Berdel W.E., Serve H. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 2000, 96(12):3907-3914.
89. Eghtedar A., Verstovsek S., Estrov Z., Burger J., Cortes J., Bivins C., Faderl S., Ferrajoli A., Borthakur G., George S., Scherle P.A., Newton R.C., Kantarjian H.M., Ravandi F. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood 2012, 119(20):4614-4618.
90. Furqan M., Akinleye A., Mukhi N., Mittal V., Chen Y., Liu D. STAT inhibitors for cancer therapy. J. Hematol. Oncol. 2013, 6:90.
91. Redell M.S., Ruiz M.J., Alonzo T.A., Gerbing R.B., Tweardy D.J. Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood 2011, 117(21):5701-5709.
92. Hayakawa F., Sugimoto K., Harada Y., Hashimoto N., Ohi N., Kurahashi S., Naoe T. A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases. Blood Cancer J. Nov 29 2013, 3:e166.
93. Lee H.J., Zhuang G., Cao Y., Du P., Kim H.J., Settleman J. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell 2014, 26(2):207-221.